Genentech and Microbiotica in IBD pact

by Lisa M. Jarvis
June 11, 2018 | APPEARED IN VOLUME 96, ISSUE 24


Genentech has teamed with Microbiotica to develop tests, drug targets, and treatments for inflammatory bowel disease. Financial specifics of the deal were not disclosed, but Microbiotica could earn up to $534 million in the collaboration. Microbiotica was spun out of the Wellcome Sanger Institute in 2016 with expertise in unraveling host-microbiome interactions. It will analyze samples from patients in clinical trials of Genentech’s IBD drugs to find biomarkers that indicate a drug is working, identify novel IBD drug targets, and develop bacteria-based therapeutics.


This article has been sent to the following recipient:

Leave A Comment

*Required to comment